Prosimy o wyszukanie innej nazwy
Nazwa | Wiek | Od | Tytuł |
---|---|---|---|
Steven G. Gourlay | 62 | 2021 | MD, CEO & Director |
Alan Keith Boyd | 66 | - | Member of Scientific Advisory Board |
Geoffrey Edward Duncan Brooke | 65 | 2017 | Independent Non-Executive Chairman |
Christina Kurre Olsen | - | 2022 | Member of Depression & Cognition Clinical Advisory Board |
Christopher Chen | - | 2022 | Member of Depression & Cognition Clinical Advisory Board |
Jeffrey L. Cummings | 73 | 2015 | Member of Xanamem Clinical Advisory Board |
Jonathan Seckl | - | - | Member of Scientific Advisory Board |
Malcolm John McComas | 68 | 2019 | Independent Non-Executive Director |
Brian R. Walker | - | - | Member of Scientific Advisory Board |
Craig W. Ritchie | - | 2015 | Chairman of Xanamem Clinical Advisory Board |
Colin Louis Masters | 76 | 2015 | Member of Xanamem Clinical Advisory Board |
George Morstyn | 73 | 2017 | Independent Non-Executive Director |
Scott Webster | - | - | Member of Scientific Advisory Board |
John Harrison | - | 2022 | Member of Depression & Cognition Clinical Advisory Board |
Nicki Vasquez | 59 | 2023 | Independent Non-Executive Director |
Dana C. Hilt | 70 | 2022 | Chief Medical Officer & Member of Depression and Cognition Clinical Advisory Board |
Czy na pewno chcesz zablokować %USER_NAME%?
Po włączeniu opcji blokady, ani Ty ani %USER_NAME% nie będziecie mogli zobaczyć swoich postów na Investing.com.
%USER_NAME% został pomyślnie dodany do Twojej Listy zablokowanych
Ponieważ właśnie odblokowałeś tę osobę, aby móc ponownie ją zablokować musi minąć 48 godzin.
Uważam, że ten komentarz jest:
Dziękujemy!
Twoje zgłoszenie zostało wysłane do naszych moderatorów w celu rewizji